摘要
Omalizumab,人源化DNA来源的单克隆抗体,可以和IgE的FC段结合,因此可以抑制IgE和相应变应原介导的免疫炎症。它和IgE FC段的结合有很高的特异性,并有可能通过B淋巴细胞抑制体液免疫。本文对它在治疗支气管哮喘、过敏性鼻炎和特行性皮炎中的应用作了综述,并总结了它的临床疗效、不良反应和应用、开发前景。
Omalizumab, a recombinant humanized monoclonal antibody, should combined with Fc segments of immunoglobulin E and then inhibit the immuno-inflammation mediated by IgE and its corresponding allergic antigen. Omalizumab has high specificity in the combination with IgE FC, which can inhibit humoral mediated immanity by B lymphocyte . This article reviews its application in bronchial asthma, allergic rhinitis and atopic dermatitis, as well as its clinical curative effect, adverse reaction and perspective of usage and development.
出处
《医学综述》
2006年第7期427-428,共2页
Medical Recapitulate
